Result of EGM and Cancellation


 

TIDMOXN 
 
RNS Number : 2486W 
Oxonica plc 
24 July 2009 
 

 
 
 
 
 
 
 
 
24th July 2009 
Oxonica plc 
("Oxonica" or the "Company") 
 
 
General Meeting Statement 
 
 
Oxonica plc, an AIM quoted leading international nanomaterials group, announces 
that the resolution proposed at the Company's General Meeting held earlier today 
relating to the proposed cancellation of the admission to trading on AIM was 
duly passed by shareholders. 
 
 
As a consequence, it is anticipated that dealing in the Company's shares on AIM 
will cease at close of trading on 3rd August 2009 and that the cancellation of 
admission to trading on AIM will be effective from 7.00am on 4 August 2009. 
 
 
As set out in the circular to shareholders, the Board has applied for the 
Company's shares to be traded on Sharemark following the delisting from AIM. 
Sharemark has issued a conditional approval for the shares to be traded on 
Sharemark subject to certain additional information being provided. While the 
Board expects to be able to satisfactorily address the requirements of 
Sharemark, it is considered unlikely that trading will be able to commence 
immediately following the delisting from AIM. Further details on Sharemark will 
be communicated to shareholders in due course. 
 
 
 
 
 
 
 
 
For further information, please contact: 
 
 
Oxonica plc                                    01865 856 700 
Kevin Matthews, Chief Executive 
Richard Clarke, Finance Director 
 
 
Panmure Gordon 020 7459 3600 
Hugh Morgan 
Andrew Potts 
 
 
 
 
Notes to Editors 
 
 
About Oxonica plc - www.oxonica.com 
 
 
Oxonica (AIM: OXN.L) is a leading nanomaterials group with products already 
launched into international markets. Oxonica's leading product is Envirox(TM) 
Fuel Borne Catalyst - a nanocatalyst improving fuel economy and reducing 
emissions. The Group has also developed Optisol(TM), a photostable UV protection 
system designed to optimise the performance of quality sunscreens and 
anti-premature ageing products, and generates licence and development revenue 
from activities in the clinical diagnostics and security markets. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 REGUSVRRKNRBUAR

Oxonica (LSE:OXN)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024